Meet the 2019 September LOL Speakers
The Land O’ Lakes Drug Metabolism and Applied Pharmacokinetics Conference brings together pharmaceutical scientists and industry experts to discuss the role of absorption, distribution, metabolism, and elimination in the pharmacokinetics and pharmacodynamics of new product candidates. The Annual DMPK Conference provides unique opportunities to discuss aspects of drug metabolism, drug transport, pharmacokinetics, and pharmacodynamics, as well as facilitate insight into problems encountered during the drug discovery and lead optimization processes.
The Land O’ Lakes DMPK Conference is designed for interaction. Our speakers are happy to converse with you and answer your questions during presentations and networking breaks.
This year we will host an optional pre-conference short course on Human PK and Dose Prediction, with the following topics/presenters:
- Small Molecule PK Prediction | Miaoran Ning, PhD, Senior Scientist, PBPK modeler, AbbVie
- Using PK/PD to Predict Human Doses for Small Molecules in Oncology | Kellie Turner, PhD, Principal Research Scientist, Lilly Chorus PK/PD
- Human Dose Projection for Large Molecules | Colin Phipps, PhD, Senior Scientist II, Translational Modeler, AbbVie
You will find our complete lineup of topics and speakers at our website.
Here is a sample of what you can expect at the 22nd Annual DMPK Conference.
Learn More and Register
 |
Hi! I have worked in the field of regulated bioanalysis for the last nine years specializing in Liquid-Chromatography Mass-Spectroscopy bioanalysis applications. I will be talking about some of the challenges associated with LC-MS/MS analysis of large and small molecule endogenous biomarkers in quantitative bioanalysis on September 10th. This topic is important because of the increased interest in biomarker determination and monitoring during the drug discovery process, and the future potential of LC-MS/MS based methodology.
Seth Bell, PhD
Associate Director, Bioanalytical Chemistry
Charles River Labs
|
Hi! I am Kari Fonseca, a Senior Principal Scientist at Pfizer Inc., supporting DMPK in the Medicine Design department. I am a project representative and support programs from early discovery to proof of concept and beyond. I will be talking about target-mediated drug disposition (TMDD) in the small molecule space on September 10th. I am excited to discuss this topic since TMDD in the small molecule space has received minimal attention, but if overlooked can lead to issues during drug discovery and development. I look forward to seeing you there.
Kari Fonseca, PhD
Senior Principal Scientist, Medicine Design
Pfizer Inc.
|
 |
 |
Hi. I am James Gosset, Principal Senior Scientist within Medicine Design at Pfizer. I represent the Pharmacokinetics, Dynamics and Metabolism discipline across Drug Discovery programs from idea to registration. I will be talking about the potential of CYP3A4 induction of an MPO inhibitor and the integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome on September 10th. I am excited to be presenting this topic as endogenous biomarkers continue to evolve as an important tool in early clinical drug-drug interaction risk assessments. I look forward to discussing this topic with all of you.
James Gosset, MSc
Associate Research Scientist DMPK Principal Senior Scientist
Pfizer Global Research and Development, Inc.
|
 |
At the Land O’ Lakes Conference on September 10, 2019, I will be talking about the use of TMDD-like pharmacokinetic models to explore strategies to optimize dose efficiency for therapeutic antibodies that bind to soluble ligands. These strategies are exciting as they offer potential to lower the therapeutic dose required, relative to conventional antibody approaches. I look forward to seeing you there!
Ryan J. Hansen, PhD
Principal Scientist Senior Research Advisor
Eli Lilly and Co.
|
Hello! I am John. I will be talking about some of the major changes to study the design and conduct of radiolabeled ADME studies in dogs and primates, with a particular emphasis on welfare, given the increasing focus that scientific research has within our political institutions, and the general public in the UK & Europe. I know we all agree that better welfare leads to better scientific outcomes in more stable animal models, and this is an area that Covance strives to take a leadership position on.
John Kendrick, PhD
DMPK Director, Global Metabolism & Pharmacokinetics
Covance
|
 |
 |
Hi! I will be talking about the advances in target-mediated drug disposition modeling of multi-specific antibodies at the September 2019 Land O’Lake Conference on September 10th. Multi-specific antibodies may be more effective by interacting with more than one target at the same time, but raise new challenges for pharmacokinetic/pharmacodynamic (PK/PD) modeling. I am excited to present and discuss this topic, and look forward to seeing you in Madison!
Mingguang Li, PhD
Lead Staff Scientist, Pharmacokinetics
Covance
|
Register Today
